Citadel Advisors
AGIO icon

Citadel Advisors’s Agios Pharmaceuticals AGIO Stock Holding History

Citadel Advisors’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.85M Sell
84,100
-125,600
-60% -$3.56M ﹤0.01% 5380
2025
Q4 		$5.71M Buy
209,700
+171,000
+442% +$6M ﹤0.01% 4084
2025
Q3 		$1.55M Buy
38,700
+7,900
+26% +$297K ﹤0.01% 6587
2025
Q2 		$1.02M Sell
30,800
-15,100
-33% -$458K ﹤0.01% 7033
2025
Q1 		$1.34M Buy
45,900
+8,000
+21% +$265K ﹤0.01% 6301
2024
Q4 		$1.25M Buy
37,900
+22,800
+151% +$1.07M ﹤0.01% 6573
2024
Q3 		$671K Sell
15,100
-5,800
-28% -$263K ﹤0.01% 7644
2024
Q2 		$901K Buy
20,900
+11,000
+111% +$397K ﹤0.01% 6799
2024
Q1 		$289K Buy
9,900
+4,700
+90% +$126K ﹤0.01% 9517
2023
Q4 		$116K Sell
5,200
-15,100
-74% -$338K ﹤0.01% 10745
2023
Q3 		$502K Buy
20,300
+11,100
+121% +$294K ﹤0.01% 8064
2023
Q2 		$261K Sell
9,200
-24,400
-73% -$607K ﹤0.01% 9333
2023
Q1 		$772K Buy
33,600
+2,900
+9% +$77K ﹤0.01% 7363
2022
Q4 		$862K Sell
30,700
-24,500
-44% -$690K ﹤0.01% 7091
2022
Q3 		$1.56M Buy
55,200
+5,700
+12% +$153K ﹤0.01% 6072
2022
Q2 		$1.1M Buy
49,500
+8,000
+19% +$181K ﹤0.01% 6814
2022
Q1 		$1.21M Buy
41,500
+12,000
+41% +$367K ﹤0.01% 7271
2021
Q4 		$970K Buy
29,500
+9,000
+44% +$362K ﹤0.01% 8043
2021
Q3 		$946K Buy
20,500
+5,300
+35% +$256K ﹤0.01% 8298
2021
Q2 		$838K Sell
15,200
-14,500
-49% -$811K ﹤0.01% 8810
2021
Q1 		$1.53M Sell
29,700
-10,900
-27% -$540K ﹤0.01% 7039
2020
Q4 		$1.76M Buy
40,600
+21,600
+114% +$854K ﹤0.01% 5623
2020
Q3 		$665K Sell
19,000
-1,900
-9% -$83.3K ﹤0.01% 6781
2020
Q2 		$1.12M Sell
20,900
-9,000
-30% -$417K ﹤0.01% 5629
2020
Q1 		$1.06M Sell
29,900
-12,300
-29% -$568K ﹤0.01% 5233
2019
Q4 		$2.02M Buy
42,200
+14,600
+53% +$552K ﹤0.01% 4413
2019
Q3 		$894K Sell
27,600
-35,400
-56% -$1.47M ﹤0.01% 5783
2019
Q2 		$3.14M Buy
63,000
+38,100
+153% +$2.04M ﹤0.01% 3780
2019
Q1 		$1.68M Sell
24,900
-13,700
-35% -$798K ﹤0.01% 4751
2018
Q4 		$1.78M Buy
38,600
+16,700
+76% +$1.03M ﹤0.01% 4328
2018
Q3 		$1.69M Buy
21,900
+5,700
+35% +$459K ﹤0.01% 4672
2018
Q2 		$1.36M Sell
16,200
-6,300
-28% -$549K ﹤0.01% 4696
2018
Q1 		$1.84M Buy
22,500
+7,300
+48% +$564K ﹤0.01% 3859
2017
Q4 		$869K Buy
15,200
+5,600
+58% +$352K ﹤0.01% 4854
2017
Q3 		$641K Sell
9,600
-2,200
-19% -$132K ﹤0.01% 4962
2017
Q2 		$607K Sell
11,800
-3,100
-21% -$158K ﹤0.01% 4846
2017
Q1 		$870K Buy
14,900
+4,900
+49% +$235K ﹤0.01% 4207
2016
Q4 		$417K Buy
10,000
+4,900
+96% +$257K ﹤0.01% 5189
2016
Q3 		$269K Sell
5,100
-15,900
-76% -$692K ﹤0.01% 5857
2016
Q2 		$880K Sell
21,000
-4,300
-17% -$212K ﹤0.01% 3721
2016
Q1 		$1.03M Buy
25,300
+4,200
+20% +$180K ﹤0.01% 3455
2015
Q4 		$1.37M Sell
21,100
-12,900
-38% -$846K ﹤0.01% 3201
2015
Q3 		$2.4M Sell
34,000
-43,300
-56% -$4.23M ﹤0.01% 2720
2015
Q2 		$8.59M Buy
77,300
+38,700
+100% +$4.17M 0.01% 1577
2015
Q1 		$3.64M Buy
38,600
+1,500
+4% +$168K ﹤0.01% 2371
2014
Q4 		$4.16M Buy
37,100
+16,700
+82% +$1.49M ﹤0.01% 2148
2014
Q3 		$1.25M Buy
+20,400
New +$879K ﹤0.01% 3435

Other funds holding AGIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Citadel Advisors's AGIO Position: Q1 2026 in Review

Citadel Advisors reduced its Agios Pharmaceuticals (AGIO) stake by 54% in Q1 2026, selling an estimated $20.7M and leaving 619,613 shares worth $21M. The position accounts for ﹤0.01% of the portfolio, ranked #2286.

Citadel Advisors first reported a position in AGIO in Q2 2014 and has held it in 42 quarters since. The position peaked at $47.1M in Q4 2024. 232 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

  • Citadel Advisors held 619,613 shares of Agios Pharmaceuticals worth $21M as of Q1 2026.
  • Citadel Advisors sold 729,355 Agios Pharmaceuticals shares in Q1 2026, an estimated $20.7M.
  • Agios Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2286 holding.
  • Citadel Advisors first reported a position in Agios Pharmaceuticals in Q2 2014 and has held it in 42 quarters since.
  • Citadel Advisors's Agios Pharmaceuticals position peaked at $47.1M in Q4 2024.
  • 232 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.